Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: NFE2 related factor 2 and NF kappa B pathway modulators - Astria Therapeutics

Next Previous
Search
Drug Profile

Research programme: NFE2 related factor 2 and NF kappa B pathway modulators - Astria Therapeutics

Alternative Names: CAT 4000; CAT-4001; Docosahexaenoic acid-monomethyl fumarate conjugate - Astria Therapeutics

Latest Information Update: 09 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Developer Astria Therapeutics
  • Class Docosahexaenoic acids; Fumarates; Omega 3 fatty acids; Small molecules
  • Mechanism of Action NF-E2-related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Friedreich's ataxia; Kidney disorders; Multiple sclerosis; Psoriasis

Most Recent Events

  • 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics
  • 28 May 2019 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
  • 28 Apr 2019 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top